Loading people...
Kent Wakeford is the Co-Founder and Co-CEO of Form Bio, a computational biology platform based in the San Francisco Bay Area, California, which he launched with a $30 million Series A. Prior to this role, he co-founded and served as Chief Operating Officer of the de-extinction company Colossal Biosciences, which has raised over $225 million in total funding. Wakeford previously operated as COO of Kabam, guiding the mobile gaming developer to an $800 million acquisition, and co-founded Integral Ad Science, an advertising technology firm that later sold for $850 million. Additionally, he served as COO and President at Skillz Inc. and was a Senior Vice President at AddThis before its $200 million sale to Oracle. His two-decade executive career focuses on scaling startups and driving shareholder value across the biotechnology, digital advertising, and consumer technology sectors.
Kent Wakeford stands as a pivotal figure in the intersection of technology, entrepreneurship, and groundbreaking scientific innovation. As a co-founder and the Vice Chairman of Colossal Biosciences, he plays a crucial role in steering a company dedicated to the ambitious and world-changing mission of de-extinction. Colossal Biosciences aims to leverage advanced genetic engineering to bring back extinct species, such as the woolly mammoth and the Tasmanian tiger, with profound implications for biodiversity and conservation. Wakeford's leadership helps bridge the gap between cutting-edge scientific research and the strategic business development necessary to achieve such monumental goals.
Wakeford's investment focus is deeply rooted in disruptive technologies and companies poised for significant societal impact. His involvement with Colossal Biosciences highlights a strong interest in biotechnology, genetic engineering, and conservation technology. Beyond biotech, his portfolio and career trajectory indicate a keen eye for deep tech, consumer internet, and the gaming sector, particularly ventures that challenge existing paradigms and create new markets. He seeks out opportunities where innovation can lead to transformative outcomes, whether in digital entertainment or the very fabric of life sciences.
His illustrious career background is marked by a consistent track record of founding, building, and leading highly successful technology companies. Prior to his work with Colossal Biosciences, Wakeford co-founded IGT (Interactive Gaming Technology), a company that revolutionized the gaming industry. He also co-founded Kabam, a leading developer and publisher of free-to-play mobile games, which achieved significant success before its acquisition by Netmarble. These experiences provided him with invaluable expertise in scaling businesses, navigating complex technological landscapes, and understanding consumer behavior on a global scale. His executive roles have consistently involved driving growth, fostering innovation, and building strong, high-performing teams.
While specific individual investments beyond his foundational role in Colossal Biosciences are often private, his history with companies like IGT and Kabam serves as a testament to his ability to identify and nurture ventures with immense potential. His strategic insights and operational acumen have been instrumental in transforming nascent ideas into market-leading enterprises. Kent Wakeford continues to be a driving force in the innovation ecosystem, actively shaping the future through his strategic investments and visionary leadership at Colossal Biosciences.
Kent Wakeford is a co-founder and the Vice Chairman of Colossal Biosciences, a pioneering company focused on de-extinction and genetic engineering. He is also a serial entrepreneur and investor with a distinguished career in technology and media.
Kent Wakeford primarily invests in disruptive technologies, with a strong focus on biotechnology, genetic engineering, deep tech, consumer internet, and gaming. He seeks ventures that offer significant societal impact and innovative solutions.
Kent Wakeford works as a co-founder and Vice Chairman at Colossal Biosciences. He is deeply involved in the company's mission to bring back extinct species through advanced genetic engineering.
